文献速递临床试验与 GCP基础与转化研究

Rezpegaldesleukin治疗中重度特应性皮炎:REZOLVE-AD 2b期诱导期最终结果

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.
PubMed 文献 · Lancet · 2026-08-22

REZOLVE-AD是一项国际双盲安慰剂对照2b期研究,评估IL-2受体激动剂rezpegaldesleukin在生物制剂初治的中重度特应性皮炎成人中的疗效与安全性。393例分析显示,三种给药方案均达到主要终点,第16周EASI评分较基线下降百分比显著优于安慰剂,且呈剂量依赖性,不良事件以轻中度注射部位反应为主。

要点

  • rezpegaldesleukin三种方案均显著改善EASI评分,优于安慰剂。
  • 最常见不良事件为注射部位反应,多为轻中度且可缓解。
  • 未观察到严重或重度不良事件风险增加,诱导期无死亡报告。

核心结论

  • 16周诱导期内,rezpegaldesleukin在中重度特应性皮炎成人中较安慰剂显著且具临床意义地改善多个终点。
  • 其不良事件谱临床可控,支持其作为新型Treg增强生物制剂进一步开发。

研究设计与样本

  • REZOLVE-AD为2b期随机双盲安慰剂对照研究,在10国107个中心开展。
  • 纳入398例生物制剂初治的中重度特应性皮炎成人,随机分配至三个rezpegaldesleukin组或安慰剂组,诱导期16周。
  • 主要终点为第16周EASI评分较基线百分比变化;393例暴露患者纳入疗效与安全性分析。

主要发现

  • rezpegaldesleukin组(n=320)发生率≥5%且高于安慰剂组(n=73)的不良事件包括注射部位反应(223[70%] vs 3[4%])、嗜酸性粒细胞增多(25[8%] vs 2[3%])、发热(20[6%] vs 2[3%])、头痛(20[6%] vs 3[4%])、上呼吸道感染(19[6%] vs 4[5%])和关节痛(16[5%] vs 1[1%])。
  • 超过99%的注射部位反应为轻中度并缓解;无严重或重度不良事件风险增加证据,诱导期无死亡报告。

临床怎么用

  • rezpegaldesleukin可能为中重度特应性皮炎生物制剂初治成人提供新的Treg靶向治疗选择。
  • 临床应用需关注注射部位反应等常见不良事件,但多数为轻中度且可缓解。

局限性

  • 本研究为2b期诱导期16周结果,长期疗效与安全性尚未报告。
  • 分析排除了两个因GCP不合规关闭的中心入组患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rezpegaldesleukin is an interleukin-2 receptor agonist that selectively expands and enhances the function of regulatory T cells (Tregs), offering a novel therapeutic approach for autoimmune and inflammatory diseases such as atopic dermatitis. We aimed to compare the efficacy and safety analyses of rezpegaldesleukin with placebo in adults with moderate-to-severe atopic dermatitis naive to biological treatments. METHODS: REZOLVE-AD was a phase 2b, randomised, double-blind, placebo-controlled study conducted in 107 community research centres or hospitals in ten countries (Australia, Bulgaria, Canada, Croatia, Czechia, Germany, Hungary, Poland, Spain, and the USA). Eligible patients were adults (aged 18 years or older) with confirmed atopic dermatitis (American Academy of Dermatology Consensus Criteria) diagnosed at least 12 months before enrolment, with moderate-to-severe disease activity defined by an Eczema Area and Severity Index (EASI) score of at least 16·0, validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of at least 3 (moderate), and at least 10% affected body surface area. Patients were randomly allocated (3:3:3:2) to receive subcutaneous rezpegaldesleukin 24 μg/kg or rezpegaldesleukin 18 μg/kg every 2 weeks, rezpegaldesleukin 24 μg/kg every 4 weeks, or placebo for 16 weeks during the induction period. Randomisation was done by an independent vendor using Randomisation and Trial Supply Management methodology via an interactive response system and was stratified by baseline disease severity (vIGA-AD 3 [moderate] vs 4 [severe]) and geographical region (North America vs rest of world). All patients, investigators, and those assessing outcomes were masked to treatment assignment. Outcomes for the induction period were assessed through week 16 and are included in this report. The primary endpoint was percentage change from baseline in EASI score at week 16. Efficacy and safety analyses were conducted in all randomly assigned patients exposed to study treatment, excluding those enrolled at two sites closed due to Good Clinical Practice non-compliance, both of which received notification of closure approximately 300 days before database lock. All missing data were imputed with multiple imputation. The trial was registered with ClinicalTrials.gov (NCT06136741). FINDINGS: 398 patients were enrolled between Nov 15, 2023, and Jan 9, 2025. A total of 393 patients were analysed (104 in the rezpegaldesleukin 24 μg/kg every 2 weeks group, 106 in the rezpegaldesleukin 18 μg/kg every 2 weeks group, 110 in the rezpegaldesleukin 24 μg/kg every 4 weeks group, and 73 in the placebo group); 203 (52%) patients were female and 190 (48%) were male. All three rezpegaldesleukin groups met the primary endpoint. Rezpegaldesleukin showed dose-dependent improvements compared with placebo in mean percentage change in EASI from baseline at week 16: -61% (SE 3·8) for rezpegaldesleukin 24 μg/kg every 2 weeks, -58% (3·8) for rezpegaldesleukin 18 μg/kg every 2 weeks, and -53% (3·7) for rezpegaldesleukin 24 μg/kg every 4 weeks versus -31% (4·5) for placebo. Treatment differences versus placebo were -30 percentage points (95% CI -41·3 to -18·0; p<0·0001) for rezpegaldesleukin 24 μg/kg every 2 weeks, -27 percentage points (-38·5 to -15·7; p<0·0001) for rezpegaldesleukin 18 μg/kg every 2 weeks, and -22 percentage points (-33·3 to -10·3; p=0·0002) for rezpegaldesleukin 24 μg/kg every 4 weeks. Treatment-emergent adverse events observed in at least 5% of rezpegaldesleukin-treated patients (n=320) and greater than placebo (n=73) included injection-site reaction (223 [70%] vs three [4%]), eosinophilia (25 [8%] vs two [3%]), pyrexia (20 [6%] vs two [3%]), headache (20 [6%] vs three [4%]), upper respiratory tract infections (19 [6%] vs four [5%]), and arthralgia (16 [5%] vs one [1%]). Nearly all (>99%) injection-site reactions were mild to moderate in severity and resolved. There was no evidence of an increased risk of serious or severe adverse events, and no deaths were reported during the induction period. INTERPRETATION: Over the 16-week induction period, rezpegaldesleukin treatment resulted in significant and clinically meaningful improvements across multiple clinical endpoints, including the primary endpoint of EASI percentage change from baseline, in comparison with placebo. Rezpegaldesleukin had a clinically favourable adverse event profile in adult patients with moderate-to-severe atopic dermatitis, supporting its further development as a novel Treg-enhancing biological treatment. FUNDING: Nektar Therapeutics.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Rosmarin D, Bieber T, et al. Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. Lancet. 2026. PMID: 42628554. doi:10.1016/S0140-6736(26)01143-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。